BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kunz D. Rethinking the use of hypnotics for treatment of insomnia in the elderly. Expert Opin Pharmacother 2021;22:953-7. [PMID: 33757383 DOI: 10.1080/14656566.2021.1900116] [Reference Citation Analysis]
2 Tavares G, Kelmann G, Tustumi F, Tundisi CN, Silveira BRB, Barbosa BMAC, Winther DB, Boutros EC, Villar GDS, Brunocilla G, Lourenção GRC, Ferreira JGA, Bernardo WM. Cognitive and balance dysfunctions due to the use of zolpidem in the elderly: a systematic review. Dement Neuropsychol 2021;15:396-404. [PMID: 34630929 DOI: 10.1590/1980-57642021dn15-030013] [Reference Citation Analysis]
3 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
4 Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology 2022;21:125-39. [DOI: 10.1016/s1474-4422(21)00436-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bland H, Li X, Mangin E, Yee KL, Lines C, Herring WJ, Gillespie G. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 2021;41:414-20. [PMID: 34181362 DOI: 10.1097/JCP.0000000000001439] [Reference Citation Analysis]
6 Esopenko C, de Souza NL, Jia Y, Parrott JS, Merkley TL, Dennis EL, Hillary FG, Velez C, Cooper DB, Kennedy J, Lewis J, York G, Menefee DS, McCauley SR, Bowles AO, Wilde EA, Tate DF. Latent Neuropsychological Profiles to Discriminate Mild Traumatic Brain Injury and Posttraumatic Stress Disorder in Active-Duty Service Members. J Head Trauma Rehabil 2022. [PMID: 35452025 DOI: 10.1097/HTR.0000000000000779] [Reference Citation Analysis]
7 Dingemanse J, Charef P, Black J, Gouws C. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects. Biomed Pharmacother 2021;133:110955. [PMID: 33190032 DOI: 10.1016/j.biopha.2020.110955] [Reference Citation Analysis]
8 Voysey Z, Fazal SV, Lazar AS, Barker RA. The sleep and circadian problems of Huntington's disease: when, why and their importance. J Neurol 2021;268:2275-83. [PMID: 33355880 DOI: 10.1007/s00415-020-10334-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Voysey ZJ, Barker RA, Lazar AS. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. Neurotherapeutics 2021;18:202-16. [PMID: 33179197 DOI: 10.1007/s13311-020-00959-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]